Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Align Technology, Inc. (ALGN) vs FMC Corp (FMC) Price & Performance

Align Technology, Inc.Trade
FMC CorpTrade

Price performance (Past 24H)

Key statistics

Align Technology, Inc. vs FMC Corp — how do they compare? Align Technology, Inc. trades at $182.87 (market cap $12.86B), while FMC Corp trades at $11.09 (market cap $1.37B). The key difference: Align Technology, Inc. is far larger — about 9.4× FMC Corp's market cap, and FMC Corp pays a 2.93% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.

ALGNFMC
Market Cap
$12.86B$1.37B
Sector
HealthBasic Materials
52-Week High
$207.19$43.90
52-Week Low
$124.88$10.80
Enterprise Value
$11.92B$5.51B
Dividend Yield
2.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Align Technology, Inc.

Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.

ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.

FMC Corp

FMC Corporation (FMC) trades at $10.91, showing minimal daily movement with a 0.18% gain. The stock faces significant fundamental challenges, including a net loss of -$2.24 billion in 2025 and negative profit margins, though recent strategic moves like a $400 million investment from Tessenderlo Group and asset sales aim to reduce debt. Technical indicators are bearish, with the stock trading near key support levels. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings but a consensus price target of $17.00 suggesting substantial upside potential from current levels.

The outlook for FMC hinges on successful debt reduction and the commercial success of new products like rimisoxafen. While the current valuation metrics (P/S: 0.4, P/B: 0.75) appear attractive, the deeply negative profitability and high debt load present significant risks. The potential for a operational turnaround exists, but investors should weigh the high risk of continued losses against the possibility of a recovery driven by new technology and improved financial health.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Align Technology, Inc.

Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).

Read more on ALGN

About FMC Corp

FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.

Read more on FMC